


Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1. (Previously Presented) A compound of formula I



wherein

each of R⁰, R¹, and R², independently is hydrogen, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkylC₁-C₈alkyl, C₅-C₁₀arylC₁-C₈alkyl, hydroxyC₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, aminoC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C₁-C₈alkoxy, hydroxyC₁-C₈alkoxy, C₁-C₈alkoxyC₁-C₈alkoxy, haloC₁-C₈alkoxy, unsubstituted or substituted C₅-C₁₀arylC₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstitued or substituted amino, C₁-C₈alkylthio, C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro;

R³ is C₁-C₈alkylsulfinyl, C₁-C₈alkylsulfonyl, C₅-C₁₀arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;

Or the pair of adjacent substituents R² and R³ forms -CH₂-NH-CO- or -CH₂-NH-SO₂- or such pairs wherein NH is substituted by C₁-C₈-alkyl;

R⁴ is hydrogen or C₁-C₈alkyl;

each of R⁵ and R⁶ independently is hydrogen, C₁-C₈alkyl, C₁-C₈alkoxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, halogen, carboxy, C₁-C₈alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro; and

each of R⁷, R⁸, R⁹, and R¹⁰ independently is C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkylC₁-C₈alkyl, C₅-C₁₀arylC₁-C₈alkyl, hydroxyC₁-C₈alkyl, C₁-

C_8 alkoxy C_1 - C_8 alkyl, amino C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, unsubstituted or substituted C_5 - C_{10} aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1 - C_8 alkoxy, hydroxy C_1 - C_8 alkoxy, C_1 - C_8 alkoxy C_1 - C_8 alkoxy, halo C_1 - C_8 alkoxy, unsubstituted or substituted C_5 - C_{10} aryl C_1 - C_8 alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstitued or substituted amino, C_1 - C_8 alkylthio, C_1 - C_8 alkylsulfinyl, C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl, halogen, carboxy, C_1 - C_8 alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano or nitro; wherein R^7 , R^8 and R^9 independently of each other can also be hydrogen;
or R^7 and R^8 , R^8 and R^9 , and/or R^9 and R^{10} form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S that is unsubstituted or substituted by C_1 - C_8 alkyl, C_1 - C_8 -alkoxy, halo- C_1 - C_8 -alkyl, hydroxyl, amino, substituted amino, halogen, carboxy, C_1 - C_8 alkoxycarbonyl, carbamoyl, cyano, or oxo;

A is C;

and salts thereof.

2. (Currently Amended) A compound of formula I according to claim 1, wherein each of R^0 or R^2 independently is hydrogen, C_1 - C_8 alkyl, hydroxy C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, unsubstituted or substituted C_5 - C_{10} aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1 - C_8 alkoxy, halo C_1 - C_8 alkoxy, C_5 - C_{10} aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, C_1 - C_8 alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R^1 is hydrogen, C_1 - C_8 alkyl, hydroxy C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, unsubstituted or substituted C_5 - C_{10} aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C_1 - C_8 alkoxy, halo C_1 - C_8 alkoxy, C_5 - C_{10} aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, C_1 - C_8 alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R^3 is C_1 - C_8 alkylsulfinyl, C_1 - C_8 -alkylsulfonyl, C_5 - C_{10} arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;

~~R^3 is C_1 - C_8 alkylsulfinyl, C_1 - C_8 -alkylsulfonyl, C_5 - C_{10} arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;~~

or the pair of adjacent substituents R² and R³ forms –CH₂-NH-CO- or CH₂-NH-SO₂- or such pairs wherein NH is substituted by C₁-C₈-alkyl;

R⁴ is hydrogen or C₁-C₈alkyl;

R⁵ is hydrogen; C₁-C₈alkyl, halogen, haloC₁-C₈alkyl, cyano or nitro;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclloxy, unsubstituted or substituted heterocycllC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;

R⁸ is hydrogen, C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclloxy, unsubstituted or substituted heterocycllC₁-C₈alkoxy, unsubstituted or substituted amino, C₁-C₈alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and

R¹⁰ is C₁-C₈alkyl, hydroxyC₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, unsubstituted or substituted heterocycllC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or

each pair of adjacent substituents R⁷ and R⁸, or R⁸ and R⁹ or R⁹ and R¹⁰, is –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH₂-O-, -CH=CH-O-, -O-CH₂-O-, or -O-CF₂-O-;

A is C.

3. (Previously Presented) A compound of formula I according to claim 1, wherein each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclloxy, unsubstituted or substituted heterocycllC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;

R¹ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclloxy, unsubstituted or substituted heterocycllC₁-C₈alkoxy, unsubstituted or substituted amino, halogen;

R^3 is $C_1\text{-}C_8$ alkylsulfinyl, $C_1\text{-}C_8$ -alkylsulfonyl, $C_5\text{-}C_{10}$ arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
or the pair of adjacent substituents R^2 and R^3 forms $-\text{CH}_2\text{-NH-CO-}$ or $\text{CH}_2\text{-NH-SO}_2^-$ or such pairs wherein NH is substituted by $C_1\text{-}C_8$ -alkyl;

R^4 is hydrogen;

R^5 is hydrogen, halogen, halo $C_1\text{-}C_8$ alkyl, or nitro;

R^6 is hydrogen;

each of R^7 and R^9 independently is hydrogen, $C_1\text{-}C_6$ alkyl, halo $C_1\text{-}C_6$ alkyl, unsubstituted or substituted $C_5\text{-}C_{10}$ aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1\text{-}C_8$ alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl $C_1\text{-}C_8$ alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R^8 is hydrogen, $C_1\text{-}C_8$ alkyl, halo $C_1\text{-}C_8$ alkyl, $C_5\text{-}C_{10}$ aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, $C_1\text{-}C_8$ alkoxy, halo $C_1\text{-}C_8$ alkoxy, $C_5\text{-}C_{10}$ aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclyl $C_1\text{-}C_8$ alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

R^{10} is $C_1\text{-}C_8$ alkyl, halo $C_1\text{-}C_8$ alkyl, $C_1\text{-}C_8$ alkoxy, unsubstituted or substituted heterocyclyl $C_1\text{-}C_8$ alkoxy, unsubstituted or substituted amino, or halogen; or
each pair of adjacent substituents R^7 and R^8 , or R^8 and R^9 or R^9 and R^{10} , is $-\text{NH-CH=CH-}$, $-\text{CH=CH-NH-}$, $-\text{NH-N=CH-}$, $-\text{CH=N-NH-}$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2^-$, $-\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_2^-$, $-\text{O-CH}_2\text{-O-}$, or $-\text{O-CF}_2\text{-O-}$;

A is C.

4. (Currently Amended) A compound of formula I according to claim 1, wherein each of R^0 or R^2 independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

R^1 is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R^3 is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or
~~the pair of adjacent substituents R^0 and R^1 , or R^1 and R^2 is $-\text{O-CH}_2\text{-O-}$, or the pair of adjacent substituents R^2 and R^3 is $-\text{CH}_2\text{-NH-CO-}$ or $-\text{CH}_2\text{-NH-SO}_2^-$;~~

R^4 is hydrogen;

R^5 is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R^6 is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

R⁸ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, haloC₁-C₈alkoxy, C₅-C₁₀aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and

R¹⁰ is C₁-C₈alkyl, haloC₁-C₈alkyl, C₁-C₈alkoxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen; or each pair of adjacent substituents R⁷ and R⁸, or R⁸ and R⁹ or R⁹ and R¹⁰, is -NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -O-CH₂-O-, or -O-CF₂-O-;

A is C.

5. (Currently Amended) A compound of formula I according to claim 1, wherein each of R⁰ or R² independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4-piperidyloxy;

R¹ is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R³ is sulfamoyl, methylsulfamoyl or propylsulfamoyl; or the pair of adjacent substituents R⁰ and R¹, or R⁴ and R² is -O-CH₂-O-, or the pair of adjacent substituents R² and R³ is -CH₂-NH-CO- or -CH₂-NH-SO₂-;

R⁴ is hydrogen;

R⁵ is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

R⁸ is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-

morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

R^{10} is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents R^7 and R^8 or R^8 and R^9 is -O-CH₂-O- or the pair of adjacent substituents R^9 and R^{10} is -NH-CH=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂- or -O-CF₂-O-;

A is C.

6. (Previously Presented) A compound of formula I according to claim 1, wherein each of R^0 , R^1 or R^2 is hydrogen;

R^3 is sulfamoyl, methylsulfamoyl or propylsulfamoyl;

R^4 is hydrogen;

R^5 is chloro or bromo;

R^6 is hydrogen;

each of R^7 and R^9 independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;

R^8 is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and

R^{10} is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or

the pair of adjacent substituents R^7 and R^8 or R^8 and R^9 is -O-CH₂-O-, or the pair of adjacent substituents R^9 and R^{10} is -NH-CH=CH-, -CH=N-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂- or -O-CF₂-O-;


A is C.

7. (Previously Presented) The compound of formula I according to claim 1, wherein each of R^0 , R^1 or R^2 is hydrogen, R^3 is methylsulfamoyl, R^4 is hydrogen, R^5 is bromo, R^6 is hydrogen, each of R^7 and R^8 is methoxy, R^9 is hydrogen, and R^{10} is methyl, and A is C.


8. (Previously Presented) The compound of formula I according to claim 1, wherein each of R⁰, R¹ or R² is hydrogen, R³ is methylsulfamoyl, R⁴ is hydrogen, R⁵ is bromo, R⁶ is hydrogen, each of R⁷ and R⁸ is hydrogen, and the pair of adjacent substituents R⁹ and R¹⁰ is -CH₂-CH₂-CH₂-, and A is C.

9. (Previously Presented) The compound 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide.

10. (Previously Presented) A process for the production of a compound of formula I according to claim 1, comprising reacting a compound of formula II



wherein R⁰, R¹, R², R³, R⁴, R⁵, and R⁶ are as defined in claim 1, and Y is a leaving group, with a compound of formula III



wherein A, R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 1;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 1, into another compound of formula I as defined in claim 1;

and recovering the resulting compound of formula I in free form or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

11. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

12. (Cancelled).

13. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 1 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

14. (Currently Amended) A method for the treatment of ~~breast tumors neoplastic diseases and immune system disorders~~ in a subject in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising same.

15. (Currently Amended) A method for the treatment ~~or prevention~~ of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

16.-20. (Cancelled).


21. (Previously Presented) The method according to claim 14, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) The method according to claim 14, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, N²-(4-[1,4]Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-[5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino]-N-isopropyl-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.

23. (Previously Presented) A compound of the formula I shown in claim 1, selected from the group of compounds with the following names or formulae:









2-[2-(2,5-dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide;
2-[5-bromo-2-(2,4-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide;








a compound of the formula



wherein Rx has one of the meanings given in the following table:







Com- ound	Rx
3-1	
3-2	
3-3	
3-4	
3-5	
3-6	






3-7	
3-8	
3-9	
3-10	
3-11	
3-12	
3-13	
3-14	

3-15	
3-16	
3-17	
3-18	
3-19	
3-20	
3-22	









3-23	
3-24	
3-25	
3-26	
3-27	
3-28	
3-29	








3-30	
3-31	
3-32	
3-33	
3-34	
3-35	
3-36	
3-37	






3-38	
3-39	
3-40	
3-41	
3-42	
3-43	







3-44	
3-45	
3-46	
3-47	
3-48	





3-49	
3-50	
3-51	
3-52	
3-53	
3-54	

3-55	
3-56	
3-57	
3-58	
3-59	
3-60	
3-61	
3-62	

3-63	
3-64	
3-65	
3-66	
3-67	
3-68	
3-69	

3-70	
3-71	
3-72	
3-73	
3-74	

3-75	
3-76	
3-77	
3-78	
3-79	
3-80	


3-81	
3-82	
3-83	
3-84	

;

2-[5-bromo-2-(2,3-[difluoromethylenedioxy]phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide;






2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide;




a compound of the formula








wherein Rx has one of the meanings given in the following table:







Com- ound	Rx

No.	
7-1	 Chemical structure 7-1: 4-(4-methylphenyl)piperazine. It consists of a piperazine ring system where the 4-position is substituted with a 4-methylphenyl group.
7-2	 Chemical structure 7-2: 4-(4-methylphenyl)piperazine-1-carboxamide. It features a piperazine ring with a 4-methylphenyl group at position 4 and a carboxamide group (-CONH ₂) at position 1.
7-3	 Chemical structure 7-3: 4-(4-methylphenyl)piperazine-4-amine. It shows a piperazine ring with a 4-methylphenyl group at position 4 and an amino group (-NH ₂) at position 4.
7-4	 Chemical structure 7-4: 4-(4-methoxyphenyl)piperazine. It has a piperazine ring with a 4-methoxyphenyl group at position 4.
7-5	 Chemical structure 7-5: 4-(4-methoxyphenyl)piperazine-1-carboxamide. It displays a piperazine ring with a 4-methoxyphenyl group at position 4 and a carboxamide group (-CONH ₂) at position 1.

7-6	
7-7	
7-8	
7-9	
7-10	
7-11	

7-12	 Chemical structure 7-12 is 4-(2-methoxyphenyl)piperazine. It consists of a piperazine ring system where the 4-position is substituted with a 2-methoxyphenyl group.
7-13	 Chemical structure 7-13 is 4-(2-methoxyphenyl)piperidin-4-amine. It features a piperidin-4-yl group attached to a 2-methoxyphenyl group, with an amide side chain (-NH ₂ -C(=O)-) at the 4-position of the piperidine ring.
7-14	 Chemical structure 7-14 is 4-(2-methoxyphenyl)piperazine-1,4-diene. It is similar to 7-12, but the piperazine ring is substituted with a diene group at the 1 and 4 positions.
7-15	 Chemical structure 7-15 is 4-(2-methoxyphenyl)piperazine-1,4-diol. It has a piperazine ring with a 2-methoxyphenyl group at the 4-position and a diol side chain (-CH(OH)-CH ₂ -) at the 1-position.
7-16	 Chemical structure 7-16 is 4-(2-methoxyphenyl)piperazine-1,4-diol, identical to 7-15 but with a chiral center at the 1-position. The diol group is shown as -CH(OH)-CH(H)-, indicating a chiral center with two hydroxyl groups and one hydrogen atom.


7-17	
7-18	
7-19	
7-20	
7-21	

7-22	
7-23	
7-24	
7-25	
7-26	
7-27	

7-28	
7-29	
7-30	




;

a compound of the formula




wherein Rx has one of the meanings given in the following table:


Com- ound	Rx
8-1	


8-2	
8-3	
8-4	



a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx
9-1	






9-6	
9-7	

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx
10-1	


10-2	
10-3	




;

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- pound	Rx
11-1	


11-2	
11-3	
11-4	

a compound of the formula




wherein Rx has one of the meanings given in the following table:




Com- pound.	Rx






a compound of the formula




wherein Ry has one of the meanings given in the following table:


Com- ound	Ry
14-1	
14-2	
14-3	



14-5	
14-6	
14-7	

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Compound	Rx
15-1	

15-2	
15-3	

a compound of the formula




wherein Ry has one of the meanings given in the following table:


Com- ound	Ry
16-1	
16-2	
16-3	

16-4	
------	--


a compound of the formula



a compound of the formula




a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound.	Rx
---------------	----

18-1









a compound of the formula








wherein Rx has one of the meanings given in the following table:


Com- ound	Rx
19-1	<p>The structure shows a piperazine ring system where one nitrogen is substituted with a 4-methoxyphenyl group and the other nitrogen is part of a piperazine ring.</p>
19-2	<p>The structure shows a piperidine ring system where one nitrogen is substituted with a 4-methoxyphenyl group and the ring is further substituted with a methylamino group.</p>
19-3	<p>The structure shows a piperidine ring system where one nitrogen is substituted with a 4-methoxyphenyl group and the ring is further substituted with a butoxy group.</p>

19-4	
19-5	
19-6	
19-7	
19-8	
19-9	


19-10	
19-11	
19-12	
19-13	
19-14	
19-15	

19-16	
19-17	
19-18	
19-19	
19-20	


19-21




19-22




19-23




19-24




19-25




19-26




19-27




19-28





19-29




19-30





19-31	
19-32	







⋮






a compound of the formula

















wherein Rx has one of the meanings given in the following table:








Com- ound	Rx
20-1	
20-2	

20-3	
20-4	
20-5	
20-6	
20-7	
20-8	


20-9	
20-10	
20-11	
20-12	
20-13	

20-14	
20-15	
20-16	
20-17	
20-18	
20-19	
20-20	

20-21	
20-22	
20-23	
20-24	
20-25	
20-26	
20-27	


20-28	
20-29	
20-30	
20-31	
20-32	
20-33	
20-34	

20-35




:

a compound of the formula




wherein Rx has one of the meanings given in the following table:




Com-pound	Rx
21-1	<p>The structure is a piperazine ring substituted with a 4-methoxyphenyl group.</p>
21-2	<p>The structure is a benzene ring substituted with a methoxy group at position 4 and a fluoride atom at position 1.</p>
21-3	<p>The structure is a piperazine ring substituted with a 4-(4-methoxyphenyl)phenyl group.</p>




a compound of the formula








wherein Rx has one of the meanings given in the following table:





Com- ound	Rx
22-1	
22-2	
22-3	

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx
23-1	
23-2	
23-3	
23-4	
23-5	

23-6	
23-7	
23-8	
23-9	


a compound of the formula



wherein Rx has one of the meanings given in the following table:


Com- ound	Rx
24-1	
24-2	
24-3	

a compound of the formula




wherein Rx has one of the meanings given in the following table:




Com- ound	Rx
25-1	








a compound of the formula




wherein Rx has one of the meanings given in the following table:


Com- ound	Rx
26-1	
26-2	
26-3	

26-4	
26-5	
26-6	
26-7	
26-8	


26-9




26-10








26-11




26-12




26-13	
26-14	
26-15	
26-16	
26-17	


26-18




26-19




26-20









26-21









26-22




26-23	 Chemical structure 26-23 is a piperidine ring substituted at the 4-position with a 2-methyl-4-methoxyphenyl group.
26-24	 Chemical structure 26-24 is a piperidine ring substituted at the 4-position with a 2-methyl-4-methoxyphenyl group, which is further substituted at the 4-position with a methylamino group.
26-25	 Chemical structure 26-25 is a piperidine ring substituted at the 4-position with a 2-methyl-4-methoxyphenyl group, which is further substituted at the 1-position with a methanamine group.
26-26	 Chemical structure 26-26 is a piperidine ring substituted at the 4-position with a 2-methoxyphenyl group.
26-27	 Chemical structure 26-27 is a piperidine ring substituted at the 4-position with a 2-methoxyphenyl group, which is further substituted at the 4-position with a hydroxymethyl group.






26-28	
26-29	
26-30	
26-31	
26-32	
26-33	





26-34	
26-35	
26-36	
26-37	
26-38	
26-39	

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx
27-1	
27-2	
27-3	
27-4	
27-5	


27-6	
27-7	
27-8	
27-9	

a compound of the formula








wherein Rx has one of the meanings given in the following table:





Com- pound	Rx




28-6	
28-7	
28-8	
28-9	
28-10	

28-11	
28-12	
28-13	
28-14	


28-15	
28-16	
28-17	
28-18	
28-19	

28-20	
28-21	
28-22	
28-23	


28-24




28-25



28-26




28-27



28-28	
28-29	
28-30	
28-31	




;

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx

29-1	
29-2	
29-3	

;


a compound of the formula



wherein Rx has one of the meanings given in the following table:


Com- ound	Rx

30-1	
30-2	
30-3	
30-4	
30-5	
30-6	



30-7	
------	---

;

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com- ound	Rx
31-1	
31-2	

;

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com-pounds	Rx
32-1	
32-2	

:

a compound of the formula




wherein Rx has one of the meanings given in the following table:

Com-pound	Rx

33-1	
33-2	






;

a compound of the formula




wherein Ry has one of the meanings given in the following table:

Com- ound	Ry
34-1	
34-2	
34-3	



34-4	
34-5	
34-6	
34-7	
34-8	

;

a compound of the formula



wherein Rx has one of the meanings given in the following table:


35-1	
35-2	

2-[5-bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N, N-dimethylbenzenesulfonamide;


2-[5-bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-5-fluoro-N-methylbenzenesulfonamide;





7-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one;

and a compound of the formula



wherein Rx has one of the meanings given in the following table:


Com- ound	Rx
12-2	

12-3	
12-4	
12-5	
12-6	


;

or a pharmaceutically acceptable salt thereof.

24. (New) A compound of the formula



wherein *Ry* has the formula



; or a pharmaceutically acceptable salt thereof.